Avatrombopag

Active ingredient description

Avatrombopag is an orally active, small molecule thrombopoietin (TPO) receptor agonist that stimulates proliferation and differentiation of megakaryocytes from bone marrow progenitor cells resulting in increased production of platelets. Avatrombopag does not compete with TPO for binding to the TPO receptor and has an additive effect with TPO on platelet production.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
B02BX08
B Blood and blood forming organs → B02 Antihemorrhagics → B02B Vitamin K and other hemostatics → B02BX Other systemic hemostatics
Discover more medicines within B02BX08

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
DOPTELET Film-coated tablet
Summary of Product Characteristics (SPC)
DOPTELET Film-coated tablet
Structured Product Labeling (SPL/PLR)
US

Medicines

Avatrombopag is the active ingredient of these drugs:

Drug
Countries
DOPTELET

Austria Estonia Finland Ireland Lithuania

Structural formula

Graphic representation of the active ingredient's molecular structure

Chemical formula: C₂₉H₃₄Cl₂N₆O₃S₂
Molecular mass: 649.65 g/mol

External identifiers

CAS Substance: 570406-98-3
DrugBank Drug: DB11995
PubChem Compound: 9852519
RxNorm Ingredient: 2045726
SNOMED-CT Concept: 770717002
Avatrombopag (substance)
UNII Identifier: 3H8GSZ4SQL
AVATROMBOPAG
 
Next: Usage >